Key Highlights
- The Extracorporeal Membrane Oxygenation Machine Market was valued at USD 634.07 million in 2024 and is forecast to reach nearly USD 973.1 million by 2032, expanding at a CAGR of 5.5% from 2025 to 2032.
- North America accounted for 45% of market revenue in 2024, supported by advanced healthcare infrastructure, high cardiovascular disease burden, and broader ECMO adoption.
- Oxygenators represented 40.2% of market revenue in 2024, making them the dominant component segment.
- Adult patients accounted for 62.0% of market revenue in 2024 and are expected to expand at the fastest rate during the forecast period.
- Portable, miniaturized ECMO systems, heparin-coated circuits, and AI-driven monitoring are shifting the market toward mobility, safety, and critical-care network expansion.
Why This Matters Now
Hospital systems are being forced to decide whether advanced respiratory and cardiac support will remain concentrated in elite centers or become a broader critical-care capability. The Extracorporeal Membrane Oxygenation Machine Market Size is growing because severe cardiopulmonary disease, aging populations, and post-pandemic ICU investment are making that decision more urgent.
The market was valued at USD 634.07 million in 2024 and is expected to reach nearly USD 973.1 million by 2032. The projected 5.5% CAGR signals a sustained shift in hospital procurement toward technologies that can support patients with severe respiratory failure, cardiac collapse, and complex post-transplant complications.
ECMO is not a routine capital purchase. It requires trained clinicians, specialized intensive-care capacity, disposable accessories, clinical protocols, and long-term service support. That makes the market strategically important for hospital networks, device manufacturers, payers, and investors focused on high-acuity care.
Market Overview
Extracorporeal membrane oxygenation is a life-sustaining technology that provides cardiac and respiratory support to patients with severe respiratory failure. The ECMO circuit includes cannulas, a pump, a blender, and an oxygenator. The system oxygenates blood and removes carbon dioxide through an extracorporeal gas-exchange device known as a membrane oxygenator.
The technology is used in severe acute respiratory distress syndrome, acute hypercapnic respiratory failure, bridge-to-lung-transplant cases, primary graft malfunction after lung transplantation, and pulmonary hypertension with right ventricular failure. Its clinical role has expanded because providers need options for patients who cannot be adequately supported through conventional ventilation or standard cardiac care.
COVID-19 accelerated adoption by highlighting ECMO’s use in treating severe ARDS. Hospitals responded by expanding ECMO-capable ICUs, while manufacturers increased supply through portable systems and heparin-coated circuits. The consequence is a market that now depends less on pandemic demand and more on the permanent buildout of advanced critical-care infrastructure.
Key Trends Driving Growth
The primary demand driver is the growing burden of cardiopulmonary disease. The report cites Centers for Disease Control and Prevention data showing that one person dies from cardiovascular disease every 37 seconds in the United States. For hospitals, this disease burden increases demand for advanced rescue technologies that can support circulation and oxygenation in critically ill patients.
Respiratory disease is adding a second layer of demand. The report cites World Health Organization data showing 255 million chronic obstructive pulmonary disease cases globally. Venovenous ECMO is used when lung support is needed, creating a direct connection between respiratory disease prevalence and the need for specialized ECMO capacity.
Population aging is also changing the market’s patient mix. The United Nations projects that the number of people aged 80 and older will rise from 143 million in 2019 to 426 million by 2050. Older adults face a higher burden of coronary heart disease and respiratory conditions, raising the probability that hospitals will require complex cardiopulmonary support.
Technology is becoming a competitive differentiator. The report identifies oxygenators, hollow pumps, and heparin-coated cannulas as important advances. Newer systems are smaller and more mobile, enabling patient transport and expanding use in emergency and neonatal care. Portable adaptors and compact circuits can help move critically ill patients between facilities, which broadens the commercial opportunity beyond large tertiary hospitals.
AI-driven monitoring is also identified as a competitive trend. Its importance lies in the potential to strengthen safety, improve monitoring, and support clinical decision-making in a treatment setting where patient condition can change rapidly. The report does not provide specific adoption figures, so market participants should view AI as an emerging capability rather than a quantified revenue driver.
Request a Free Sample Report for Comprehensive Market Insights
Segment Insights
- Dominant Segment: Oxygenators
Oxygenators accounted for 40.2% of Extracorporeal Membrane Oxygenation Machine Market revenue in 2024. Their high cost and frequent exchange requirements support segment value. Mechanical failure, pump head thrombosis, and acute oxygenator thrombosis are cited as key reasons for replacement, creating recurring demand for hospitals and suppliers. - Fastest-Growing Segment: Adult Patients
Adult patients accounted for 62.0% of market revenue in 2024 and are expected to expand at the fastest rate through the forecast period. Tobacco use, smoking, alcohol use, sedentary lifestyles, and the rising burden of heart and respiratory disease are increasing demand for advanced support among adult patients. - Modality Opportunity: Veno-Arterial ECMO
The veno-arterial category is expected to grow at a strong CAGR during the forecast period. Its use in cardiac arrest patients and life-support measures that restore blood circulation positions it as a major opportunity in cardiac critical care. - Respiratory Support Opportunity: Venovenous ECMO
Venovenous ECMO held a considerable share in 2024 and is expected to grow at a profitable pace. Its ability to support oxygen and carbon dioxide exchange makes it relevant for severe respiratory failure and pulmonary support needs. - Pediatric and Neonatal Care Opportunity
Pediatric patients held a sizable share and are expected to grow rapidly. Rising pulmonary and cardiac ailments among children support demand, while neonatal-focused equipment broadens the addressable critical-care market.
Regional Growth Story
North America led the market with 45% of revenue in 2024. The region benefits from advanced healthcare infrastructure, higher adoption of ECMO systems, technology development, and a substantial cardiovascular and respiratory disease burden. This leadership gives suppliers a large installed base but also creates pressure to prove clinical value, reliability, and cost efficiency.
The United States remains the central market within North America. The report cites 659,000 annual heart disease deaths in the country, representing one in four deaths, and approximately 805,000 heart attacks. These figures create a large clinical need for advanced cardiac support, while rising government healthcare spending and high asthma-related costs expand the rationale for critical-care investment.
The report identifies Europe, including Germany and the UK, as part of the market’s regional scope. Germany is represented by companies such as Xenios, MAQUET Holding, Novalung, and Medos Medizintechnik, while the UK is included in the distribution footprint of the ProLUNG extracorporeal carbon dioxide removal system. However, the supplied report does not disclose country-level market values, reimbursement policies, or adoption rates for Germany or the UK.
Asia Pacific is the second major regional opportunity. The report identifies China, Japan, India, and South Korea within the regional market scope. Terumo leads in Asia Pacific with membrane oxygenators and portable ECMO devices, while MicroPort is gaining traction through cost-effective solutions. The source does not provide country-specific spending, reimbursement, or market-size data, so those details should not be assumed.
Competitive Landscape
The market is led by Medtronic, LivaNova, Getinge, Terumo, and MicroPort Scientific. Their strength comes from research and development investment, strategic acquisitions, product launches, distribution reach, and the ability to support high-acuity clinical settings.
Medtronic is positioned through advanced ECMO systems and minimally invasive technology focus. LivaNova benefits from its cardiopulmonary portfolio and Sorin Group legacy in oxygenators and perfusion systems. Getinge draws on Maquet expertise in critical care and emphasizes high-performance systems with safety features.
Terumo’s position in Asia Pacific is strengthened by membrane oxygenators and portable ECMO devices. MicroPort is expanding through cost-effective offerings and broader global reach. Regional companies such as Braile Biomédica and Jafron Biomedical serve local demand with more affordable alternatives but lack the global scale of market leaders.
The competitive battle is shifting from equipment sales to system capability. Suppliers that combine compact design, biocompatibility, safety features, service coverage, and clinical training will be better positioned to win hospital contracts. The need for skilled ECMO teams also favors companies that can support education and implementation.
Recent Developments
- Getinge launched a neonatal version of its Servo-c ventilator on June 30, 2025, capable of supporting premature infants weighing as little as 500 grams. The launch expands its relevance in neonatal critical care and strengthens its position in hospitals investing in advanced infant respiratory support.
- Fresenius Medical Care’s heart and lung division, including Novalung, secured a national group purchasing agreement with Premier, Inc. on November 19, 2024. The agreement enables more than 4,350 Premier member hospitals in the United States to access the FDA-cleared Novalung ECMO system under pre-negotiated terms, improving market reach and affordability.
- Estor S.p.A partnered with Nikkiso Europe on October 23, 2023, to distribute the ProLUNG extracorporeal carbon dioxide removal system across the UK, Ireland, Germany, Spain, Thailand, and Colombia. The partnership broadens access to minimally invasive respiratory support and signals demand for alternatives that can serve patients before full ECMO escalation is required.
Strategic Implications
Hospital leaders should treat ECMO as a network-care decision. The technology requires ICU capability, specialist staffing, transport planning, and referral protocols. Hospitals that build these systems effectively can improve access for patients with severe respiratory and cardiac failure.
Manufacturers must address the market’s cost barrier. ECMO requires expensive equipment, disposable accessories, hospitalization, and a complete specialist team. Typical hospital stays for patients receiving ECMO support are one to two weeks and may extend depending on disease severity. Companies that improve device durability, simplify workflow, and support cost-effective deployment will have a stronger value proposition.
Payers and policymakers face a related challenge. ECMO can reduce in-hospital mortality, but its cost profile requires clear evidence of patient benefit and appropriate use. Reimbursement and purchasing agreements will increasingly shape access, particularly as hospitals seek predictable costs for high-acuity therapies.
Future Outlook
The Extracorporeal Membrane Oxygenation Machine Market will favor companies that make advanced life support more portable, clinically manageable, and economically accessible, while laggards will remain tied to narrow equipment sales.
Analyst Perspective
“ECMO technology is moving beyond a specialized rescue intervention toward a more structured critical-care capability for hospitals managing severe cardiac and respiratory failure,” said Komal Patil, Analyst at Maximize Market Research. “The companies that combine safer systems, portable design, clinical support, and broader access models will be best placed to capture the next phase of demand.”
About Maximize Market Research
Maximize Market Research Pvt. Ltd. (MMR) is a global market research and consulting company that provides reliable, data-focused, and practical business insights. The firm serves a wide range of industries, including healthcare, pharmaceuticals, technology, automotive, electronics, chemicals, personal care, and consumer goods. Through market forecasts, competitive analysis, strategic consulting, and industry impact assessments, MMR helps organizations understand changing market conditions, identify growth opportunities, and make informed business decisions for long-term success.
Contact Us
2nd Floor, Navale IT Park Phase 3
Pune Banglore Highway, Narhe
Pune, Maharashtra 411041, India
+91 9607365656
sales@maximizemarketresearch.com
